These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
121 related articles for article (PubMed ID: 12804139)
1. Radiation improves intratumoral gene therapy for induction of cancer vaccine in murine prostate carcinoma. Hillman GG; Xu M; Wang Y; Wright JL; Lu X; Kallinteris NL; Tekyi-Mensah S; Thompson TC; Mitchell MS; Forman JD Hum Gene Ther; 2003 May; 14(8):763-75. PubMed ID: 12804139 [TBL] [Abstract][Full Text] [Related]
2. Curative antitumor immune response is optimal with tumor irradiation followed by genetic induction of major histocompatibility complex class I and class II molecules and suppression of Ii protein. Wang Y; Xu M; Che M; Von Hofe E; Abbas A; Kallinteris NL; Lu X; Liss ZJ; Forman JD; Hillman GG Hum Gene Ther; 2005 Feb; 16(2):187-99. PubMed ID: 15761259 [TBL] [Abstract][Full Text] [Related]
3. Generating MHC Class II+/Ii- phenotype after adenoviral delivery of both an expressible gene for MHC Class II inducer and an antisense Ii-RNA construct in tumor cells. Hillman GG; Kallinteris NL; Li J; Wang Y; Lu X; Li Y; Wu S; Wright JL; Slos P; Gulfo JV; Humphreys RE; Xu M Gene Ther; 2003 Aug; 10(17):1512-8. PubMed ID: 12900767 [TBL] [Abstract][Full Text] [Related]
4. Vaccination with an adenoviral vector encoding the tumor antigen directly linked to invariant chain induces potent CD4(+) T-cell-independent CD8(+) T-cell-mediated tumor control. Sorensen MR; Holst PJ; Pircher H; Christensen JP; Thomsen AR Eur J Immunol; 2009 Oct; 39(10):2725-36. PubMed ID: 19637230 [TBL] [Abstract][Full Text] [Related]
5. Dual antigen target-based immunotherapy for prostate cancer eliminates the growth of established tumors in mice. Karan D; Dubey S; Van Veldhuizen P; Holzbeierlein JM; Tawfik O; Thrasher JB Immunotherapy; 2011 Jun; 3(6):735-46. PubMed ID: 21668311 [TBL] [Abstract][Full Text] [Related]
6. Tumor irradiation followed by intratumoral cytokine gene therapy for murine renal adenocarcinoma. Hillman GG; Slos P; Wang Y; Wright JL; Layer A; De Meyer M; Yudelev M; Che M; Forman JD Cancer Gene Ther; 2004 Jan; 11(1):61-72. PubMed ID: 14681727 [TBL] [Abstract][Full Text] [Related]
7. Antigen-specific tumor vaccine efficacy in vivo against prostate cancer with low class I MHC requires competent class II MHC. Neeley YC; McDonagh KT; Overwijk WW; Restifo NP; Sanda MG Prostate; 2002 Nov; 53(3):183-91. PubMed ID: 12386918 [TBL] [Abstract][Full Text] [Related]
8. Tumor immunotherapy by converting tumor cells to MHC class II-positive, Ii protein-negative phenotype. Lu X; Kallinteris NL; Li J; Wu S; Li Y; Jiang Z; Hillman GG; Gulfo JV; Humphreys RE; Xu M Cancer Immunol Immunother; 2003 Oct; 52(10):592-8. PubMed ID: 12827305 [TBL] [Abstract][Full Text] [Related]
9. Vaccination with recombinant adenoviruses and dendritic cells expressing prostate-specific antigens is effective in eliciting CTL and suppresses tumor growth in the experimental prostate cancer. Kim S; Lee JB; Lee GK; Chang J Prostate; 2009 Jun; 69(9):938-48. PubMed ID: 19267351 [TBL] [Abstract][Full Text] [Related]
11. Radiotherapy and MVA-MUC1-IL-2 vaccine act synergistically for inducing specific immunity to MUC-1 tumor antigen. Hillman GG; Reich LA; Rothstein SE; Abernathy LM; Fountain MD; Hankerd K; Yunker CK; Rakowski JT; Quemeneur E; Slos P J Immunother Cancer; 2017; 5():4. PubMed ID: 28116088 [TBL] [Abstract][Full Text] [Related]
12. Dendritic cell based PSMA immunotherapy for prostate cancer using a CD40-targeted adenovirus vector. Williams BJ; Bhatia S; Adams LK; Boling S; Carroll JL; Li XL; Rogers DL; Korokhov N; Kovesdi I; Pereboev AV; Curiel DT; Mathis JM PLoS One; 2012; 7(10):e46981. PubMed ID: 23056548 [TBL] [Abstract][Full Text] [Related]
13. Class II transactivator-induced MHC class II expression in pancreatic cancer cells leads to tumor rejection and a specific antitumor memory response. Ekkirala CR; Cappello P; Accolla RS; Giovarelli M; Romero I; Garrido C; Garcia-Lora AM; Novelli F Pancreas; 2014 Oct; 43(7):1066-72. PubMed ID: 24987872 [TBL] [Abstract][Full Text] [Related]
14. External beam radiation of tumors alters phenotype of tumor cells to render them susceptible to vaccine-mediated T-cell killing. Chakraborty M; Abrams SI; Coleman CN; Camphausen K; Schlom J; Hodge JW Cancer Res; 2004 Jun; 64(12):4328-37. PubMed ID: 15205348 [TBL] [Abstract][Full Text] [Related]
15. CIITA-induced MHC class II expression in mammary adenocarcinoma leads to a Th1 polarization of the tumor microenvironment, tumor rejection, and specific antitumor memory. Mortara L; Castellani P; Meazza R; Tosi G; De Lerma Barbaro A; Procopio FA; Comes A; Zardi L; Ferrini S; Accolla RS Clin Cancer Res; 2006 Jun; 12(11 Pt 1):3435-43. PubMed ID: 16740768 [TBL] [Abstract][Full Text] [Related]
16. Synergistic antitumor effect of chemotactic-prostate tumor-associated antigen gene-modified tumor cell vaccine and anti-CTLA-4 mAb in murine tumor model. Li N; Qin H; Li X; Zhou C; Wang D; Ma W; Lin C; Zhang Y; Wang S; Zhang S Immunol Lett; 2007 Nov; 113(2):90-8. PubMed ID: 17913245 [TBL] [Abstract][Full Text] [Related]
18. Tumor rejection by gene transfer of the MHC class II transactivator in murine mammary adenocarcinoma cells. Meazza R; Comes A; Orengo AM; Ferrini S; Accolla RS Eur J Immunol; 2003 May; 33(5):1183-92. PubMed ID: 12731043 [TBL] [Abstract][Full Text] [Related]
19. In vivo gene transfer of CD40 ligand into colon cancer cells induces local production of cytokines and chemokines, tumor eradication and protective antitumor immunity. Sun Y; Peng D; Lecanda J; Schmitz V; Barajas M; Qian C; Prieto J Gene Ther; 2000 Sep; 7(17):1467-76. PubMed ID: 11001366 [TBL] [Abstract][Full Text] [Related]
20. Versatile prostate cancer treatment with inducible caspase and interleukin-12. Nikitina EY; Desai SA; Zhao X; Song W; Luo AZ; Gangula RD; Slawin KM; Spencer DM Cancer Res; 2005 May; 65(10):4309-19. PubMed ID: 15899823 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]